Also categorized in BoardNews:
Six Years Later, The Problem at HP is Still the Board
x hide permanently

Shire Faces Criticism on CEO Pay Policy as Crunch Week Looms

(Reuters) - Shire ( SHP.L ), the $47 billion (£33.1 billion) rare disease drugmaker being stalked by Japan’s Takeda Pharmaceutical ( 4502.T ), faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches...

Mentions: Investment ISS Japan